Literature DB >> 23377337

Clearance of invasive melanoma with topical imiquimod.

Summer D Moon1, James M Spencer.   

Abstract

A 93-year-old woman presented with biopsy-proven invasive melanoma of 2.75 mm depth, arising from a melanoma in situ. Standard treatment of this depth would be an extensive and mutilating excision, which presented a therapeutic dilemma. Imiquimod has the ability to clear melanoma in situ, but its effect on invasive melanoma is unknown. After a thorough discussion with the patient, we decided to attempt to treat the melanoma in situ with topical imiquimod and then excise the smaller invasive component. Following 5 weeks of topical imiquimod therapy, the area where the nodular melanoma had previously been was excised. Histological examination of the excisional specimen revealed no residual melanoma detected. In this case, it appears that 5 weeks of topical imiquimod therapy completely cleared an invasive melanoma of 2.75 mm depth, as well as clearing the component of melanoma in situ. The patient was followed for 14 months with no evidence of recurrence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23377337

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

Review 1.  Melanoma treatment: from conventional to nanotechnology.

Authors:  Harshita Mishra; Pawan K Mishra; Adam Ekielski; Manu Jaggi; Zeenat Iqbal; Sushama Talegaonkar
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-09       Impact factor: 4.553

Review 2.  Skin Penetration Enhancement Strategies Used in the Development of Melanoma Topical Treatments.

Authors:  Supreeda Tambunlertchai; Sean M Geary; Aliasger K Salem
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 3.603

3.  Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.

Authors:  Sebastian Schölch; Conrad Rauber; Alexandra Tietz; Nuh N Rahbari; Ulrich Bork; Thomas Schmidt; Christoph Kahlert; Uwe Haberkorn; Mark A Tomai; Kenneth E Lipson; Rafael Carretero; Jürgen Weitz; Moritz Koch; Peter E Huber
Journal:  Oncotarget       Date:  2015-03-10

4.  Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.

Authors:  Alexis Courbet; Nicole Bec; Caroline Constant; Christian Larroque; Martine Pugniere; Safia El Messaoudi; Zahraa Zghaib; Sonia Khier; Carine Deleuze-Masquefa; Florence Gattacceca
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

5.  Recurrent in situ melanoma successfully treated with ingenol mebutate.

Authors:  Marion Mansuy; Nazli Nikkels-Tassoudji; Jorge E Arrese; Andree Rorive; Arjen F Nikkels
Journal:  Dermatol Ther (Heidelb)       Date:  2014-04-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.